Advertisement

Topics

A Treatment-Specific Predictive Biomarker in Metastatic Castration-Resistant Prostate Cancer

19:00 EST 29 Nov 2016 | NEJM

Patients who test positive for the androgen-receptor splice variant 7 (AR-V7) benefit more from taxanes than from AR-directed therapy.

Original Article: A Treatment-Specific Predictive Biomarker in Metastatic Castration-Resistant Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "A Treatment-Specific Predictive Biomarker in Metastatic Castration-Resistant Prostate Cancer"

Quick Search
Advertisement